Carfilzomib: A cause of drug associated thrombotic microangiopathy

被引：28
|
作者：
Qaqish, Ibrahim [1 ]
Schlam, Ilana M. [2 ]
Chakkera, Harini A. [1 ]
Fonseca, Rafael [2 ]
Adamski, Jill [3 ]
机构：
[1] Mayo Clin Arizona, Dept Nephrol, 5777 East Mayo Blvd, Phoenix, AZ 85054 USA
[2] Mayo Clin Arizona, Dept Internal Med, 5777 East Mayo Blvd, Phoenix, AZ 85054 USA
[3] Mayo Clin Arizona, Dept Lab Med & Pathol, 5777 East Mayo Blvd, Phoenix, AZ 85054 USA
来源：
TRANSFUSION AND APHERESIS SCIENCE | 2016年 / 54卷 / 03期
关键词：
Thrombotic microangiopathy; Therapeutic plasma exchange; Apheresis; BORTEZOMIB; PATIENT; EXPERIENCE;
D O I：
10.1016/j.transci.2016.03.002
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Carfilzomib is a selective proteosome inhibitor approved for treatment of relapsed and refractory multiple myeloma. Recent reports have linked exposure to carfilzomib with development of thrombotic microangiopathy (TMA). We describe two cases of biopsy proven thrombotic microangiopathy that occurred after the initiation of carfilzomib (dosed at 32 mg/m(2) and 23 mg/m(2), respectively) for relapsed multiple myeloma. Both patients were managed with discontinuation of the drug, therapeutic plasma exchange (TPE) and supportive care. Hemoglobin, platelets and renal function did not improve with TPE. TMA resolved with creatinine returning to baseline several weeks after discontinuation of the drug. The outcomes suggest that TPE is not beneficial for treating carfilzomib-induced TMA. (C) 2016 Elsevier Ltd. All rights reserved.
引用
收藏
页码：401 / 404
页数：4
相关论文
共 50 条
  • [41] Is thrombotic microangiopathy associated with antitumoral activity?
    Chopin, N
    Alexandre, J
    Chapron, C
    Moachon, L
    Goldwasser, F
    GYNECOLOGIC ONCOLOGY, 2006, 101 (03) : 549 - 550
  • [42] Lupus nephritis and associated thrombotic microangiopathy
    Schuster, Antonia
    Banas, Bernhard
    Bergler, Tobias
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2024, 83 (08): : 675 - 678
  • [43] Cancer-associated thrombotic microangiopathy
    Babu, Govind K.
    Bhat, Gita R.
    ECANCERMEDICALSCIENCE, 2016, 10
  • [44] Thrombotic Microangiopathy Associated with Interferon Beta
    Hunt, David
    Kavanagh, David
    Drummond, Iain
    Weller, Belinda
    Bellamy, Chris
    Overell, James
    Evans, Stephen
    Jackson, Andrew
    Chandran, Siddharthan
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (13): : 1270 - 1271
  • [45] Syndromes of thrombotic microangiopathy associated with pregnancy
    George, James N.
    Nester, Carla M.
    McIntosh, Jennifer J.
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2015, : 644 - 648
  • [46] Thrombotic Microangiopathy Associated with Tuberculous Infection
    Masumoto, Shoichi
    Tada, Manami
    Katsuma, Ai
    Minami, Eri
    Katagiri, Daisuke
    Shibata, Maki
    Hinoshita, Fumihiko
    INTERNAL MEDICINE, 2011, 50 (17) : 1825 - 1828
  • [47] Thrombotic microangiopathy associated with proteasome inhibitors
    Lodhi, Ahad
    Kumar, Abhishek
    Saqlain, Muhammad U.
    Suneja, Manish
    CLINICAL KIDNEY JOURNAL, 2015, 8 (05) : 632 - 636
  • [48] Impact of treatment and outcomes for patients with posttransplant drug-associated thrombotic microangiopathy
    Epperla, Narendranath
    Hemauer, Kathleen
    Hamadani, Mehdi
    Friedman, Kenneth D.
    Kreuziger, Lisa Baumann
    TRANSFUSION, 2017, 57 (11) : 2775 - 2781
  • [49] Cyclosporine as cause of thrombotic microangiopathy after renal transplantation
    Miller, BW
    Hmiel, SP
    Schnitzler, MA
    Brennan, DC
    AMERICAN JOURNAL OF KIDNEY DISEASES, 1997, 29 (05) : 813 - 813
  • [50] Malignant hypertension as a cause of thrombotic microangiopathy in a pediatric patient
    Ozcakar, Z. B.
    Yalcinkaya, F.
    Ensari, A.
    Kendirli, T.
    Ekim, M.
    Fitoz, S.
    PEDIATRIC NEPHROLOGY, 2008, 23 (09) : 1662 - 1662
12345